Triple Negative Breast Cancer, "I Won't Back Down!": Living Beyond Beast Cancer Conference Philadelphia 2018

What is TNBC

WHAT IS TRIPLE NEGATIVE BREAST CANCER?

Just in recent years, Triple Negative Breast Cancer (TNBC) has sparked interest in the news where instead of calling the tumor as ER-negative, PR-negative, and HER2-negative; researchers began using the shorthand term, "Triple Negative," dubbed the "new type" of breast cancer. Being Triple Negative, you don't have a targeted therapy and your only treatment option is chemotherapy.

Triple Negative Breast Cancer is seen in about 15% of all breast cancers. TNBC is a very aggressive cancer that tends to strike younger women, pre-menopause, especially among African-American women and women who have BRCA1 mutations. The tumor tends to be fast growing and is less likely to show up on an annual mammogram. TNBC is more likely to metastasis early on; has a high rate of recurrence in the first 2-3 years from diagnosis and has a poorer prognosis than other types of breast cancer due to lack of specific, targeted treatment for TNBC.

Friday, March 22, 2019

Living Beyond Beast Cancer Conference Philadelphia 2018

On September 28, 2018, I attended the Living Beyond Breast Cancer Conference that was co-hosted by The Triple Negative Breast Cancer Foundation in Philadelphia. A lot of promising research is still ongoing for Triple Negative Breast Cancer... PARP Inhibitors was FDA approved in October 2018 for BRCA positive metastatic TNBC. Immunotherapy and Antibody-drug conjugates is also emerging in TNBC clinical trials with favorable results in complete response in metastatic Triple Negative Breast Cancer.

My beautiful hotel room view of
Philadelphia skyline

No One Fights Alone!
TNBC sisters Sara K. and Melissa

Hayley Dinerman, Co-founder and President of
Triple Negative Breast Cancer Foundation
https://tnbcfoundation.org

Diagnosed with Triple Negative Breast Cancer
before the age of 60?

Promising Immunotherapy research
for TNBC still in clinical trials

The safety of Pembrolizumab Monotherapy
has demonstrated as being favorable as
a first-line therapy with PD-L1 positive
Metastatic Triple Negative Breast Cancer.